Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Depreciation and Depletion (2024 - 2025)

Anika Therapeutics (ANIK) has disclosed Depreciation and Depletion for 2 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion rose 25.0% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.4 million, a 8.0% increase, with the full-year FY2025 number at $5.4 million, up 8.0% from a year prior.
  • Depreciation and Depletion was $1.5 million for Q4 2025 at Anika Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.5 million in Q4 2025 to a low of $1.2 million in Q1 2024.